EA201491599A1 - Антитела к матриксной металлопротеиназе 9 - Google Patents

Антитела к матриксной металлопротеиназе 9

Info

Publication number
EA201491599A1
EA201491599A1 EA201491599A EA201491599A EA201491599A1 EA 201491599 A1 EA201491599 A1 EA 201491599A1 EA 201491599 A EA201491599 A EA 201491599A EA 201491599 A EA201491599 A EA 201491599A EA 201491599 A1 EA201491599 A1 EA 201491599A1
Authority
EA
Eurasian Patent Office
Prior art keywords
matrix metalloproteinase
antibodies
mmp
functional fragment
binding proteins
Prior art date
Application number
EA201491599A
Other languages
English (en)
Inventor
Джоан И. Адамкевич
Виктория СМИТ
Дзун Тай
Майкл Дж. Хоукинс
Original Assignee
Джилид Байолоджикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/027160 external-priority patent/WO2013130078A1/en
Application filed by Джилид Байолоджикс, Инк. filed Critical Джилид Байолоджикс, Инк.
Publication of EA201491599A1 publication Critical patent/EA201491599A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

В соответствии с настоящим изобретением предложены композиции и способы их применения, в которых применяют связывающие белки, например антитела и их антигенсвязывающие фрагменты, которые связываются с белком матриксной металлопротеиназы-9 (ММП-9) (ММП-9 также известна как желатиназа-В), например, связывающие белки, содержащие тяжелую цепь иммуноглобулина (Ig) (или ее функциональный фрагмент) и легкую цепь Ig (или ее функциональный фрагмент).
EA201491599A 2012-02-29 2013-02-28 Антитела к матриксной металлопротеиназе 9 EA201491599A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261605181P 2012-02-29 2012-02-29
PCT/US2012/027160 WO2013130078A1 (en) 2012-02-29 2012-02-29 Antibodies to matrix metalloproteinase 9
US201361755444P 2013-01-22 2013-01-22
PCT/US2013/028456 WO2013130905A1 (en) 2012-02-29 2013-02-28 Antibodies to matrix metalloproteinase 9

Publications (1)

Publication Number Publication Date
EA201491599A1 true EA201491599A1 (ru) 2015-05-29

Family

ID=49003113

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491599A EA201491599A1 (ru) 2012-02-29 2013-02-28 Антитела к матриксной металлопротеиназе 9

Country Status (23)

Country Link
US (2) US9732156B2 (ru)
EP (2) EP2819697A4 (ru)
JP (3) JP6144286B2 (ru)
KR (1) KR20140130513A (ru)
CN (2) CN107184974A (ru)
AP (1) AP2014007921A0 (ru)
AU (1) AU2013203619B2 (ru)
BR (1) BR112014021081A2 (ru)
CA (1) CA2865501A1 (ru)
CL (1) CL2014002258A1 (ru)
CO (1) CO7061039A2 (ru)
CR (1) CR20140451A (ru)
EA (1) EA201491599A1 (ru)
EC (1) ECSP14020644A (ru)
HK (4) HK1204926A1 (ru)
MD (1) MD20140108A2 (ru)
MX (2) MX2014010447A (ru)
MY (1) MY167236A (ru)
NZ (1) NZ629178A (ru)
PH (1) PH12014501927A1 (ru)
SG (2) SG11201405273YA (ru)
WO (1) WO2013130905A1 (ru)
ZA (1) ZA201406318B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA34527B1 (fr) 2010-08-27 2013-09-02 Gilead Biologics Inc Anticorps contre la metalloproteinase de matrice 9
BR112013028808A2 (pt) 2011-05-10 2016-09-06 Nestec Sa métodos de caracterização de perfil de atividade de doença para a gestão de terapia personalizada
AP2014007921A0 (en) 2012-02-29 2014-09-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
MD20140107A2 (ru) 2012-02-29 2015-03-31 Gilead Biologics, Inc. Антитела против матричной металлопротеиназы 9
KR102571391B1 (ko) 2013-09-13 2023-08-29 제넨테크, 인크. 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
CA3174012A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
JP6749838B2 (ja) 2014-01-30 2020-09-02 コヒラス・バイオサイエンシズ・インコーポレイテッド かん流培地
JP2017507949A (ja) * 2014-02-27 2017-03-23 ギリアード サイエンシーズ， インコーポレイテッド マトリックスメタロプロテイナーゼ９に対する抗体およびその使用の方法
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
JO3664B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme أجسام مضادة لـ tigit
CN115925931A (zh) * 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
US20170174788A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
KR101783907B1 (ko) * 2016-03-15 2017-10-10 다이노나(주) ＣＤ66ｃ에 대한 항체와 화학치료제를 포함하는 폐암 예방 또는 치료용 약학조성물
CA3019003A1 (en) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
TWI676482B (zh) * 2017-03-23 2019-11-11 高雄醫學大學 盤基蛋白結構域受體１的抑制劑及活化劑及其用途
CA3064529C (en) 2017-05-31 2021-12-14 Prometheus Biosciences, Inc. Methods for assessing mucosal healing in crohn's disease patients
EP3656861A4 (en) 2017-07-18 2021-04-07 Daiichi Sankyo Company, Limited ACTIVE MMP9-BINDING PEPTIDE
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
IL264768A (en) * 2019-02-10 2020-08-31 Sagi Irit ANTI-MATRIX METALLOPROTEINASE 7 (MMP-7) inhibitory antibody and its use
US11332546B2 (en) 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
WO2020237092A2 (en) * 2019-05-21 2020-11-26 The Regents Of The University Of California Mmp-9 antibodies and methods of use thereof
WO2021202592A2 (en) * 2020-03-30 2021-10-07 Oregon Health & Science University Monoclonal antibodies for intracellular delivery of payloads
WO2023154814A2 (en) * 2022-02-09 2023-08-17 Sera Prognostics, Inc. Shbg and ibp4 antibodies and methods using same
CN114292834B (zh) * 2022-03-09 2022-05-31 天津辅元生物医药科技有限公司 一种融合蛋白酶及其制备方法、其在提取i型胶原蛋白中的应用以及该i型胶原蛋白的用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
DE69412466T2 (de) 1993-11-30 1999-04-29 Fuji Yakuhin Kogyo Kk Neue metalloprotease und kodierende dna dafür
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
JP2003524587A (ja) 1998-06-05 2003-08-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用
DE60042487D1 (de) 1999-07-13 2009-08-13 Univ Southern California Methode und zusammensetzung zur angiogenese-inhibierung mit antagonisten gegen mmp-9 und beta1-integrine
US7101975B1 (en) 1999-07-13 2006-09-05 University Of Southern California Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins
AU2002235692A1 (en) 2001-02-23 2002-09-04 Biophage Inc. Methods and compositions for preventing and treating neutrophil-mediated diseases
SE0102298D0 (sv) 2001-06-27 2001-06-27 Astrazeneca Ab Crystal structure of enzyme and uses thereof
WO2003006006A1 (en) 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
WO2003044058A2 (en) 2001-11-23 2003-05-30 Universite Catholique De Louvain Medical use of antibodies directed against human matrix metalloproteinases or related tissue proteinases for the treatment of abnormal uterine bleeding and endometriosis
NZ538384A (en) 2002-09-06 2009-04-30 Alexion Pharma Inc Treatment for asthma using a compound which binds to or otherwise blocks the generation and/or activity of one or more complement components reptors, such as, C5a receptors
WO2004076614A2 (de) 2003-02-27 2004-09-10 Bernd Hinzmann Humane nukleinsäuresequenzen aus prostatakarzinomen
US7524938B2 (en) 2003-04-04 2009-04-28 Yeda Research And Development Co., Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
US7534604B2 (en) * 2004-01-16 2009-05-19 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
WO2006037513A1 (en) 2004-10-09 2006-04-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with matrix metalloproteinase 9 (mmp9)
WO2007094842A2 (en) * 2005-12-02 2007-08-23 Genentech, Inc. Binding polypeptides and uses thereof
WO2007005426A2 (en) 2005-06-29 2007-01-11 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of acute coronary syndrome
CN101370832B (zh) * 2005-12-02 2014-07-02 健泰科生物技术公司 结合多肽及其用途
WO2007144781A2 (en) 2006-04-21 2007-12-21 Diagnotech Pty. Ltd. Diagnostic methods and kits utilizing antibodies for metalloproteases
WO2008088864A2 (en) 2007-01-18 2008-07-24 The Trustess Of Columbia University In The City Of New York Matrix metalloproteinase-9-related methods
EP2155691B1 (en) 2007-02-23 2016-01-13 Yeda Research and Development Co. Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
WO2008154439A1 (en) 2007-06-08 2008-12-18 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
HUE025283T2 (en) 2007-08-02 2016-03-29 Gilead Biologics Inc LOX and LOX2 inhibitors and their use
RU2474433C2 (ru) 2007-08-15 2013-02-10 ЙЕДА РЕСЕАРЧ ЭНД ДЕВЕЛОПМЕНТ КО. ЛТД, эт ве Вайзманн Институте оф Сайнсе Регуляторы ммр-9 и их применение
AU2008338421A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
JP2011517320A (ja) 2008-03-03 2011-06-02 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質およびメタロプロテアーゼ２結合タンパク質
JP2011517662A (ja) * 2008-03-03 2011-06-16 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質
US20100098659A1 (en) * 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
EP2350305A4 (en) 2008-10-22 2013-03-06 Dyax Corp COMBINATION TREATMENTS WITH PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISEASES
WO2010059543A1 (en) * 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
DE102009030321A1 (de) * 2009-06-24 2011-01-05 Siemens Aktiengesellschaft Verfahren zur Abbildung von Tumorgewebe
EP3216805A1 (en) 2010-01-27 2017-09-13 Yeda Research and Development Co. Ltd Antibodies that inhibit metalloproteins
CN105622757A (zh) 2010-02-04 2016-06-01 吉联亚生物科技有限公司 结合赖氨酰氧化酶样2（loxl2）的抗体和其使用方法
US8896483B2 (en) * 2010-07-15 2014-11-25 Evgeny Markin Method of automatic target angle tracking by monopulse radar under conditions of interference distorting location characteristic
MA34527B1 (fr) * 2010-08-27 2013-09-02 Gilead Biologics Inc Anticorps contre la metalloproteinase de matrice 9
US8003110B1 (en) * 2011-01-24 2011-08-23 Matthias W. Rath Metalloproteinase oligopeptides and their therapeutic use
MD20140107A2 (ru) 2012-02-29 2015-03-31 Gilead Biologics, Inc. Антитела против матричной металлопротеиназы 9
AP2014007921A0 (en) 2012-02-29 2014-09-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9

Also Published As

Publication number Publication date
EP3255063A3 (en) 2018-02-07
HK1204981A1 (en) 2015-12-11
EP2819697A1 (en) 2015-01-07
US20130224210A1 (en) 2013-08-29
EP3255063A2 (en) 2017-12-13
AU2013203619B2 (en) 2015-02-26
HK1244671A1 (zh) 2018-08-17
WO2013130905A1 (en) 2013-09-06
CO7061039A2 (es) 2014-09-19
US20180002446A1 (en) 2018-01-04
BR112014021081A2 (pt) 2017-07-04
EP2819697A4 (en) 2016-03-09
JP2017178952A (ja) 2017-10-05
SG10201610788VA (en) 2017-03-30
MY167236A (en) 2018-08-14
ZA201406318B (en) 2016-07-27
CN107184974A (zh) 2017-09-22
AU2013203619A1 (en) 2013-09-19
CN104271156B (zh) 2017-06-16
ECSP14020644A (es) 2015-09-30
US9732156B2 (en) 2017-08-15
HK1204926A1 (en) 2015-12-11
PH12014501927A1 (en) 2014-11-24
MX2014010447A (es) 2015-06-23
JP6343368B2 (ja) 2018-06-13
JP2018150343A (ja) 2018-09-27
JP6144286B2 (ja) 2017-06-07
CN104271156A (zh) 2015-01-07
CR20140451A (es) 2014-11-17
MX2018007630A (es) 2023-04-12
HK1248246A1 (zh) 2018-10-12
CA2865501A1 (en) 2013-09-06
KR20140130513A (ko) 2014-11-10
NZ629178A (en) 2016-09-30
CL2014002258A1 (es) 2015-02-20
JP2015509959A (ja) 2015-04-02
SG11201405273YA (en) 2014-09-26
AP2014007921A0 (en) 2014-09-30
MD20140108A2 (ru) 2015-03-31

Similar Documents

Publication Publication Date Title
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
CY1123518T1 (el) Ανθρωπινα αντισωματα enanti-tau
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
MX2022010487A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
EA201591153A1 (ru) Антитела, связывающиеся с tl1a, и их применение
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
PE20150023A1 (es) Proteinas de union a antigeno st2
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
PE20120549A1 (es) Proteinas biespecificas de union a antigenos
EA201790757A1 (ru) Связывающие антиген cd27l белки
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
EA201291065A1 (ru) Антитела против vla-4
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
EA201590918A1 (ru) Антитела к bmp-6
EA201990895A1 (ru) Антитела к о1 и варианты их применения
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
EA202191187A1 (ru) Антитела к ctla4, фрагменты антител, их иммуноконъюгаты и их применение
TH148296B (th) แอนติบอดีต้านเมทริกซ์เมทัลโลโปรตีเนส 9 (Antibodies to matrix metalloproteinase 9)